LeMaitre Vascular (NASDAQ: LMAT) SVP exercises stock options on Form 4

Rhea-AI Filing Summary

LeMaitre Vascular’s Senior Vice President of Operations, Trent G. Kamke, reported exercising stock options and acquiring common shares. On January 8, 2026, he exercised options covering 1,229 shares of common stock at $37.29 per share and 1,115 shares at $48.60 per share. These transactions increased his directly held common stock to 5,646 shares after the first exercise and 6,761 shares after the second.

Following these exercises, he continued to hold stock options directly. After the first transaction, he held 3,690 stock options with a $37.29 exercise price, originally granted on December 2, 2020 and expiring on December 2, 2027. After the second, he held 5,085 stock options with a $48.60 exercise price, granted on December 11, 2021 and expiring on December 11, 2028. Footnotes state these options are fully vested and exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kamke Trent G

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR , INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior V. P., Operations

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		M		1,229(1)	A	$37.29	5,646	D
Common Stock	01/08/2026		M		1,115(1)	A	$48.6	6,761	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$37.29	01/08/2026		M			1,229	12/02/2020(2)	12/02/2027	Common Stock	1,229	$0	3,690	D
Stock Option (Right to Buy)	$48.6	01/08/2026		M			1,115	12/11/2021(2)	12/11/2028	Common Stock	1,115	$0	5,085	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. This option is fully vested and exercisable.

	/s/ Laurie A. Churchill, Attorney-in-fact	01/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did LeMaitre Vascular (LMAT) report on this Form 4?

The filing reports that Trent G. Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised stock options and acquired additional shares of the company’s common stock on January 8, 2026.

How many LeMaitre Vascular (LMAT) shares did the executive acquire in these transactions?

On January 8, 2026, he acquired 1,229 shares of common stock at $37.29 per share and 1,115 shares at $48.60 per share through option exercises.

What is Trent G. Kamke’s ownership in LeMaitre Vascular (LMAT) after these Form 4 transactions?

After the reported transactions, he directly owned 5,646 shares of common stock following the first exercise and 6,761 shares following the second, as well as remaining stock options listed in Table II.

What stock options did the LeMaitre Vascular (LMAT) executive exercise and what remains outstanding?

He exercised options for 1,229 shares with a $37.29 exercise price (grant date December 2, 2020, expiration December 2, 2027) and 1,115 shares with a $48.60 exercise price (grant date December 11, 2021, expiration December 11, 2028). After these transactions, he held 3,690 and 5,085 stock options in those respective grants.

Are the LeMaitre Vascular (LMAT) stock options reported on this Form 4 vested?

Yes. A footnote states that the reported stock options are fully vested and exercisable.

Is the LeMaitre Vascular (LMAT) insider’s ownership reported as direct or indirect on this Form 4?

The filing indicates that both the common stock and the remaining stock options reported are held with direct (D) ownership.